.jpeg)
General information:
GLP-1 Agonist Medications
Glucagon-like peptides receptor agonists (GLP-1) medications are incretin mimetics. They were developed to help control type two diabetes by lowering blood glucose, regulating metabolic responses and promoting weight loss. These medications have been found to help control appetite at the hypothalamus, regulate insulin’s release from the pancreas and slow the rate the stomach empties after a meal.
Several GLP-1 have been approved by the FDA to help with weight loss in nondiabetic individuals. These include Semaglutide (Wegovy) and Tirzepetide(Zepbound). Many other GLP-1 agonist are FDA approved for treatment of type two diabetes including Semaglutide (Ozempic), Tirzepatide (Mounjaro), Dulaglutide (Trulicity), and Semaglutide (Rebelsus).
Glucagon-like peptides receptor agonists (GLP-1) medications are incretin mimetics. They were developed to help control type two diabetes by lowering blood glucose, regulating metabolic responses and promoting weight loss. These medications have been found to help control appetite at the hypothalamus, regulate insulin’s release from the pancreas and slow the rate the stomach empties after a meal.
Several GLP-1 have been approved by the FDA to help with weight loss in nondiabetic individuals. These include Semaglutide (Wegovy) and Tirzepetide(Zepbound). Many other GLP-1 agonist are FDA approved for treatment of type two diabetes including Semaglutide (Ozempic), Tirzepatide (Mounjaro), Dulaglutide (Trulicity), and Semaglutide (Rebelsus).